These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 8658681)

  • 1. Safety, tolerability, and pharmacokinetics of Sandimmun Neoral: conversion study in stable renal transplant recipients.
    Tsang WK; Ho YW; Tong KL; Chan WH; Chan A
    Transplant Proc; 1996 Jun; 28(3):1330-2. PubMed ID: 8658681
    [No Abstract]   [Full Text] [Related]  

  • 2. Experience with clinical use of Sandimmun Neoral in renal transplant patients.
    Min ZL; Zhao M; Zhu YH; Qi J; Wang LM; Wang YW
    Transplant Proc; 1996 Jun; 28(3):1356-7. PubMed ID: 8658692
    [No Abstract]   [Full Text] [Related]  

  • 3. Conversion from conventional Sandimmun to Neoral therapy in stable renal transplant recipients.
    Løkkegaard H; Asmundsson P; Clausen P; Dieperink H; Hansen JM; Heaf J; Jensen SB; Kornerup HJ; Madsen S; Pedersen EB; Poulsen JV; Rasmussen K
    Transplant Proc; 1996 Aug; 28(4):2199-201. PubMed ID: 8769199
    [No Abstract]   [Full Text] [Related]  

  • 4. Cyclosporine pharmacokinetic profiles in stable renal allograft recipients converting from Sandimmun to Neoral.
    Vathsala A; Lee WT; Jacob E; Woo KT
    Transplant Proc; 1996 Jun; 28(3):1324-6. PubMed ID: 8658678
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and tolerability of CyA microemulsion formulation (Sandimmun Neoral) in stable renal transplant patients after 24 months of treatment. German Neoral Study Group.
    Offermann G; Korn A
    Transplant Proc; 1996 Aug; 28(4):2204-6. PubMed ID: 8769201
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety and tolerability of Sandimmun Neoral vs Sandimmun in de novo renal transplant patients after 24 months' treatment. German Neoral Study Group.
    Buchholz B; Korn A
    Transplant Proc; 1996 Aug; 28(4):2187-8. PubMed ID: 8769195
    [No Abstract]   [Full Text] [Related]  

  • 7. A study to assess the efficacy, tolerability, and safety of a new oral formulation of Sandimmun--Sandimmun Neoral--in stable renal transplant patients.
    Rosental R; Bicans J; Berzina R; Zezina L
    Transplant Proc; 1995 Dec; 27(6):3436-7. PubMed ID: 8540038
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetic analysis of Neoral conversion in pediatric and adult renal transplant recipients with poor absorption of Sandimmune.
    Pescovitz MD; Henson S; Bodziak K; Book BK; Gonin J; Jindal RM; Leapman SB; Milgrom ML; Filo RS
    Transplant Proc; 1996 Aug; 28(4):2165-8. PubMed ID: 8769189
    [No Abstract]   [Full Text] [Related]  

  • 9. A randomized, controlled, double-blind study of the safety and tolerability of Sandimmun Neoral in stable renal transplant patients. Argentine Multicentre Study Group.
    Massari PU; Grosso S; de Boccardo G; Vásquez MC; Schiavelli RO; Sabbatiello RR; Casadei DH; Rial MC; Jost LJ; Túrin MD; Agost Carreño C A; Maggiora EC; Gadea MM
    Transplant Proc; 1996 Dec; 28(6):3365-7. PubMed ID: 8962310
    [No Abstract]   [Full Text] [Related]  

  • 10. A randomized, controlled trial to assess the safety of switching stable renal transplant patients from Sandimmun to Sandimmun Neoral.
    Loo CS; Morad Z; Lim TO; Fan KS; Suleiman AB
    Transplant Proc; 1996 Jun; 28(3):1328-9. PubMed ID: 8658680
    [No Abstract]   [Full Text] [Related]  

  • 11. Cyclosporine pharmacokinetics in stable renal transplant patients: effect of formulation Sandimmun versus Consupren versus Neoral.
    Masri MA; Barbari A; Stephan A; Kamel G; Frem G; Younan F; Rizk S; Moubarak R; Karam A
    Transplant Proc; 1996 Jun; 28(3):1318-20. PubMed ID: 8658676
    [No Abstract]   [Full Text] [Related]  

  • 12. Conversion from Sandimmune to Neoral and induction therapy with Neoral in pediatric renal transplant recipients.
    Hoyer PF; Boekenkamp A; Vester U; Offner G; Brodehl J
    Transplant Proc; 1996 Aug; 28(4):2259-61. PubMed ID: 8769218
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and tolerability of Neoral in transplant recipients.
    Feutren G; Wong R; Jin J; Niese D; Mellein B
    Transplant Proc; 1996 Aug; 28(4):2177-82. PubMed ID: 8769193
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety and tolerability of a new oral formulation of cyclosporin A, Sandimmun Neoral, in renal transplant patients.
    Taesch S; Niese D
    Transpl Int; 1994; 7 Suppl 1():S263-6. PubMed ID: 11271220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion from cyclosporine Sandimmune to cyclosporine Neoral in the stable renal transplant population.
    Griffin PJ; Moore RH; Jurewicz WA; Lord RH; Webley Y; Jenkins J
    Transplant Proc; 1997; 29(1-2):303. PubMed ID: 9123007
    [No Abstract]   [Full Text] [Related]  

  • 16. Conversion to cyclosporine microemulsion (Neoral) in stable renal transplant patients: results from a single center.
    Cossu M; Satta R; Branca GF; Pala PG; Serra G; Satta RP; Sorba G
    Transplant Proc; 1998 Aug; 30(5):1762-3. PubMed ID: 9723271
    [No Abstract]   [Full Text] [Related]  

  • 17. Conversion from Sandimmune to Neoral in stable renal and pancreas transplant recipients enhances cyclosporine absorption.
    Chapman JR; O'Connell PJ; Bovington KJ; Allen RD
    Transplant Proc; 1996 Aug; 28(4):2293-5. PubMed ID: 8769229
    [No Abstract]   [Full Text] [Related]  

  • 18. Cyclosporine neoral pharmacokinetics in kidney and heart transplant patients.
    Schiavelli R; Sgrosso JL; Sabbatiello R; Castro C; Ahualli L; Pattin M; Vazquez MC
    Transplant Proc; 1996 Dec; 28(6):3343-4. PubMed ID: 8962299
    [No Abstract]   [Full Text] [Related]  

  • 19. The Neoral formulation: improved correlation between cyclosporine trough levels and exposure in stable renal transplant recipients.
    Kahan BD; Dunn J; Fitts C; Van Buren D; Wombolt D; Pollak R; Carson R; Alexander JW; Chang C; Choc M
    Transplant Proc; 1994 Oct; 26(5):2940-3. PubMed ID: 7940928
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacokinetics, efficacy, and safety of Iminoral compared with Neoral in healthy volunteers and renal transplant recipients.
    Sayyah M; Argani H; Pourmand GR; Amini H; Ahmadiani A
    Transplant Proc; 2007 May; 39(4):1214-8. PubMed ID: 17524936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.